Breaking News

Financial Report: Evotec 3Q

November 8, 2012

Revenues decline in the quarter, up 8% YTD


3Q Revenues: €22.2 million (-16%)

3Q Earnings: €5.9 million (-30%)

YTD Revenues: €64.2 million (+8%)

YTD Earnings: €7.5 million (-18%)

Comments: YTD growth was driven by an increase in revenues from the company’s drug discovery alliances, Andromeda/Teva, Boehringer Ingelheim (€2.5 million) and Novartis, and revenues from upfront payments from the CureBeta partnership with Janssen and contributions from acquisitions of Evotec Munich and Evotec San Francisco.